伴共病的银屑病管理共识（2026版）

doi:10.35541/cjd.20240495

中华皮肤科杂志 ›› 2026, Vol. 59 ›› Issue (3): 193-207.doi: 10.35541/cjd.20240495

伴共病的银屑病管理共识（2026版）

中华医学会皮肤性病学分会银屑病专业委员会

中华医学会皮肤性病学分会银屑病专业委员会

收稿日期:2024-09-14 修回日期:2025-02-23 发布日期:2026-03-03
通讯作者: 张学军 E-mail:ayzxj@vip.sina.com

Expert consensus on management of psoriasis with comorbidities （2026）

Committee on Psoriasis, Chinese Society of Dermatology

Committee on Psoriasis, Chinese Society of Dermatology

Received:2024-09-14 Revised:2025-02-23 Published:2026-03-03
Contact: Zhang Xuejun E-mail:ayzxj@vip.sina.com

摘要/Abstract

摘要： 【摘要】银屑病是一种慢性、复发性、炎症性、系统性疾病，常与代谢综合征、心血管疾病、糖尿病、精神类疾病等多种共病并存，严重影响患者的身心健康。积极管理银屑病共病对规范银屑病诊疗路径、改善临床预后具有重要意义。本共识基于既往国内外指南和临床共识，结合最新研究进展，系统归纳总结了伴共病的银屑病的管理方案，并对其对治疗、预防和康复进行深入阐述，旨在为我国银屑病诊疗相关专业人员提供科学的共病管理参考。

关键词: 银屑病, 慢性病共病, 疾病管理, 专家共识

Abstract: 【Abstract】 Psoriasis is a chronic, recurrent, inflammatory systemic disease that often coexists with various comorbidities, such as metabolic syndrome, cardiovascular diseases, diabetes, and psychiatric disorders, significantly impacting patients' physical and mental health. Proactively managing psoriasis comorbidities is of great importance for standardizing diagnostic and treatment pathways and improving clinical outcomes. Based on previous Chinese and international guidelines, clinical consensus, and the latest research advancements, this consensus systematically summarizes the management strategies for psoriasis with comorbidities, provides an in-depth elucidation of the treatment, prevention, and rehabilitation of psoriasis comorbidities, aiming to offer a scientific reference to healthcare professionals involved in psoriasis diagnosis and treatment in China.

Key words: Psoriasis, Multiple chronic conditions, Disease management, Expert consensus

中华医学会皮肤性病学分会银屑病专业委员会. 伴共病的银屑病管理共识（2026版）[J]. 中华皮肤科杂志, 2026,59(3):193-207. doi:10.35541/cjd.20240495

Committee on Psoriasis, Chinese Society of Dermatology. Expert consensus on management of psoriasis with comorbidities （2026）[J]. Chinese Journal of Dermatology, 2026, 59(3): 193-207.doi:10.35541/cjd.20240495

参考文献 197

［1］	丁晓岚, 王婷琳, 沈佚葳, 等. 中国六省市银屑病流行病学调查［J］. 中国皮肤性病学杂志, 2010,24（7）:598⁃601.
［2］	Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence［J］. J Invest Dermatol, 2013,133（2）:377⁃385. DOI: 10.1038/jid. 2012.339.
［3］	Henseler T, Christophers E. Disease concomitance in psoriasis［J］. J Am Acad Dermatol, 1995,32（6）:982⁃986. DOI: 10.1016/0190⁃9622（95）91336⁃x.
［4］	Aurangabadkar SJ. Comorbidities in psoriasis［J］. Indian J Dermatol Venereol Leprol, 2013,79 Suppl 7:S10⁃17. DOI: 10. 4103/0378⁃6323.115506.
［5］	中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南（2023版）［J］. 中华皮肤科杂志, 2023,56（7）:573⁃625. DOI: 10.35541/cjd.20220839.
［6］	中华医学会皮肤性病学分会银屑病专业委员会. 银屑病生物制剂达标治疗专家共识［J］. 中华皮肤科杂志, 2023,56（3）:191⁃203. DOI: 10.35541/cjd.20220652.
［7］	Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and hypertension: a systematic review and meta⁃analysis of observational studies［J］. J Hypertens, 2013,31（3）:433⁃442; discussion 442⁃443. DOI: 10.1097/HJH.0b013e32835bcce1.
［8］	Chiu HY, Chang WL, Shiu MN, et al. Psoriasis is associated with a greater risk for cardiovascular procedure and surgery in patients with hypertension: a nationwide cohort study［J］. J Dermatol, 2018,45（12）:1381⁃1388. DOI: 10.1111/1346⁃8138. 14654.
［9］	Nast A, Smith C, Spuls PI, et al. EuroGuiDerm Guideline on the systemic treatment of psoriasis vulgaris ⁃ part 2: specific clinical and comorbid situations［J］. J Eur Acad Dermatol Venereol, 2021,35（2）:281⁃317. DOI: 10.1111/jdv.16926.
［10］	Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: implications for management［J］. J Am Acad Dermatol, 2017,76（3）:393⁃403. DOI: 10.1016/j.jaad.2016.07.065.
［11］	Dauden E, Blasco AJ, Bonanad C, et al. Position statement for the management of comorbidities in psoriasis［J］. J Eur Acad Dermatol Venereol, 2018,32（12）:2058⁃2073. DOI: 10.1111/jdv. 15177.
［12］	Kakarala CL, Hassan M, Belavadi R, et al. Beyond the skin plaques: psoriasis and its cardiovascular comorbidities［J］. Cureus, 2021,13（11）:e19679. DOI: 10.7759/cureus.19679.
［13］	Eder L, Joshi AA, Dey AK, et al. Association of tumor necrosis factor inhibitor treatment with reduced indices of subclinical atherosclerosis in patients with psoriatic disease［J］. Arthritis Rheumatol, 2018,70（3）:408⁃416. DOI: 10.1002/art.40366.
［14］	Gelfand JM, Shin DB, Alavi A, et al. A phase IV, randomized, double⁃blind, placebo⁃controlled crossover study of the effects of ustekinumab on vascular inflammation in psoriasis （the VIP⁃U trial）［J］. J Invest Dermatol, 2020,140（1）:85⁃93. DOI: 10.1016/j.jid.2019.07.679.
［15］	von Stebut E, Reich K, Thaçi D, et al. Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks［J］. J Invest Dermatol, 2019,139（5）:1054⁃1062. DOI: 10.1016/j.jid.2018.10.042.
［16］	Lambert J, Segaert S, Ghislain PD, et al. Practical recommendations for systemic treatment in psoriasis according to age, pregnancy, metabolic syndrome, mental health, psoriasis subtype and treatment history （BETA⁃PSO: Belgian evidence⁃based treatment advice in psoriasis; part 1）［J］. J Eur Acad Dermatol Venereol, 2020,34（8）:1654⁃1665. DOI: 10.1111/jdv. 16684.
［17］	Amatore F, Villani AP, Tauber M, et al. French guidelines on the use of systemic treatments for moderate⁃to⁃severe psoriasis in adults［J］. J Eur Acad Dermatol Venereol, 2019,33（3）:464⁃483. DOI: 10.1111/jdv.15340.
［18］	Pannu S, Rosmarin D. Psoriasis in patients with metabolic syndrome or type 2 diabetes mellitus: treatment challenges［J］. Am J Clin Dermatol, 2021,22（3）:293⁃300. DOI: 10.1007/s40257⁃021⁃00590⁃y.
［19］	Wan MT, Shin DB, Hubbard RA, et al. Psoriasis and the risk of diabetes: a prospective population⁃based cohort study［J］. J Am Acad Dermatol, 2018,78（2）:315⁃322.e1. DOI: 10.1016/j.jaad. 2017.10.050.
［20］	Casagrande SS, Menke A, Cowie CC. No association between psoriasis and diabetes in the U.S. population［J］. Diabetes Res Clin Pract, 2014,104（3）:e58⁃e60. DOI: 10.1016/j.diabres.2014. 04.009.
［21］	Armesto S, Santos⁃Juanes J, Galache⁃Osuna C, et al. Psoriasis and type 2 diabetes risk among psoriatic patients in a Spanish population［J］. Australas J Dermatol, 2012,53（2）:128⁃130. DOI: 10.1111/j.1440⁃0960.2011.00802.x.
［22］	Wolf N, Quaranta M, Prescott NJ, et al. Psoriasis is associated with pleiotropic susceptibility loci identified in typeⅡ diabetes and Crohn disease［J］. J Med Genet, 2008,45（2）:114⁃116. DOI: 10.1136/jmg.2007.053595.
［23］	Eirís N, González⁃Lara L, Santos⁃Juanes J, et al. Genetic variation at IL12B, IL23R and IL23A is associated with psoriasis severity, psoriatic arthritis and type 2 diabetes mellitus［J］. J Dermatol Sci, 2014,75（3）:167⁃172. DOI: 10.1016/j.jdermsci.2014.05.010.
［24］	Wang H, Wang Z, Rani PL, et al. Identification of PTPN22, ST6GAL1 and JAZF1 as psoriasis risk genes demonstrates shared pathogenesis between psoriasis and diabetes［J］. Exp Dermatol, 2017,26（11）:1112⁃1117. DOI: 10.1111/exd.13393.
［25］	von Stebut E, Boehncke WH, Ghoreschi K, et al. IL⁃17A in psoriasis and beyond: cardiovascular and metabolic implications［J］. Front Immunol, 2019,10:3096. DOI: 10.3389/fimmu.2019. 03096.
［26］	Li Xh, Zhang ZT, Yu YJ, et al. Activation of the STING⁃IRF3 pathway involved in psoriasis with diabetes mellitus［J］. J Cell Mol Med, 2022,26（8）:2139⁃2151. DOI: 10.1111/jcmm.17236.
［27］	Gelfand JM. Psoriasis, type 2 diabetes mellitus, and obesity: weighing the evidence［J］. JAMA Dermatol, 2016,152（7）:753⁃754. DOI: 10.1001/jamadermatol.2016.0670.
［28］	Lee MS, Lin RY, Lai MS. Increased risk of diabetes mellitus in relation to the severity of psoriasis, concomitant medication, and comorbidity: a nationwide population⁃based cohort study［J］. J Am Acad Dermatol, 2014,70（4）:691⁃698. DOI: 10.1016/j.jaad. 2013.11.023.
［29］	Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management［J］. J Eur Acad Dermatol Venereol, 2012,26 Suppl 2:3⁃11. DOI: 10.1111/j.1468⁃3083. 2011.04410.x.
［30］	Mahil SK, McSweeney SM, Kloczko E, et al. Does weight loss reduce the severity and incidence of psoriasis or psoriatic arthritis? A critically appraised topic［J］. Br J Dermatol, 2019,181（5）:946⁃953. DOI: 10.1111/bjd.17741.
［31］	Jin Y, Zhang F, Yang S, et al. Combined effects of HLA⁃Cw6, body mass index and waist⁃hip ratio on psoriasis vulgaris in Chinese Han population［J］. J Dermatol Sci, 2008,52（2）:123⁃129. DOI: 10.1016/j.jdermsci.2008.04.016.
［32］	Tupikowska⁃Marzec M, Kolačkov K, Zdrojowy⁃Wełna A, et al. the influence of fto polymorphism rs9939609 on obesity, some clinical features, and disturbance of carbohydrate metabolism in patients with psoriasis［J］. Biomed Res Int, 2019,2019:7304345. DOI: 10.1155/2019/7304345.
［33］	Francisco V, Pino J, Campos⁃Cabaleiro V, et al. Obesity, fat mass and immune system: role for leptin［J］. Front Physiol, 2018,9:640. DOI: 10.3389/fphys.2018.00640.
［34］	Bavoso NC, Pinto JM, Soares M, et al. Psoriasis in obesity: comparison of serum levels of leptin and adiponectin in obese subjects ⁃ cases and controls［J］. An Bras Dermatol, 2019,94（2）:192⁃197. DOI: 10.1590/abd1806⁃4841.20197716.
［35］	Gelfand JM, Abuabara K. Diet and weight loss as a treatment for psoriasis［J］. Arch Dermatol, 2010,146（5）:544⁃546. DOI: 10. 1001/archdermatol.2010.92.
［36］	Gisondi P, Del Giglio M, Di Francesco V, et al. Weight loss improves the response of obese patients with moderate⁃to⁃severe chronic plaque psoriasis to low⁃dose cyclosporine therapy: a randomized, controlled, investigator⁃blinded clinical trial［J］. Am J Clin Nutr, 2008,88（5）:1242⁃1247. DOI: 10.3945/ajcn. 2008.26427.
［37］	Huang YH, Yang LC, Hui RY, et al. Relationships between obesity and the clinical severity of psoriasis in Taiwan［J］. J Eur Acad Dermatol Venereol, 2010,24（9）:1035⁃1039. DOI: 10.1111/j.1468⁃3083.2010.03573.x.
［38］	Jensen P, Zachariae C, Christensen R, et al. Effect of weight loss on the severity of psoriasis: a randomized clinical study［J］. JAMA Dermatol, 2013,149（7）:795⁃801. DOI: 10.1001/jamadermatol. 2013.722.
［39］	李斌, 董玲玲, 聂振华. 银屑病与肥胖的相关性研究［J］. 中国中西医结合皮肤性病学杂志, 2020,19（6）:614⁃616. DOI: 10. 3969/j.issn.1672⁃0709.2020.06.038.
［40］	Langman G, Hall PM, Todd G. Role of non⁃alcoholic steatohepatitis in methotrexate⁃induced liver injury［J］. J Gastroenterol Hepatol, 2001,16（12）:1395⁃1401. DOI: 10.1046/j.1440⁃1746.2001.02644.x.
［41］	Onsun N, Akaslan TÇ, Sallahoglu K, et al. Effects of TNF inhibitors and an IL12/23 inhibitor on changes in body weight and adipokine levels in psoriasis patients: a 48⁃week comparative study［J］. J Dermatolog Treat, 2022,33（3）:1727⁃1732. DOI: 10.1080/09546634.2021.1901845.
［42］	Wu MY, Yu CL, Yang SJ, et al. Change in body weight and body mass index in psoriasis patients receiving biologics: a systematic review and network meta⁃analysis［J］. J Am Acad Dermatol, 2020,82（1）:101⁃109. DOI: 10.1016/j.jaad.2019.07.103.
［43］	Smith CH, Yiu Z, Bale T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update［J］. Br J Dermatol, 2020,183（4）:628⁃637. DOI: 10.1111/bjd.19039.
［44］	中国血脂管理指南修订联合专家委员会. 中国血脂管理指南（2023年）［J］. 中国循环杂志, 2023,38（3）:237⁃271. DOI: 10. 3969/j.issn.1000⁃3614.2023.03.001.
［45］	Gelfand JM, Shin DB, Duffin KC, et al. A randomized placebo⁃controlled trial of secukinumab on aortic vascular inflammation in moderate⁃to⁃severe plaque psoriasis （VIP⁃S）［J］. J Invest Dermatol, 2020,140（9）:1784⁃1793. DOI: 10. 1016/j.jid.2020. 01.025.
［46］	Gui XY, Yu XL, Jin HZ, et al. Prevalence of metabolic syndrome in Chinese psoriasis patients: a hospital⁃based cross⁃sectional study［J］. J Diabetes Investig, 2018,9（1）:39⁃43. DOI: 10.1111/jdi.12663.
［47］	刘玉, 韩建文, 崔梓榆, 等. 寻常性银屑病、泛发性脓疱型银屑病与血脂、血糖、血压的相关性［J］. 中国皮肤性病学杂志, 2019,33（3）:270⁃274. DOI: 10.13735/j.cjdv.1001⁃7089.20180 6149.
［48］	Luan C, Chen X, Zhu Y, et al. Potentiation of psoriasis⁃like inflammation by pcsk9［J］. J Invest Dermatol, 2019,139（4）:859⁃867. DOI: 10.1016/j.jid.2018.07.046.
［49］	Ni C, Chiu MW. Psoriasis and comorbidities: links and risks［J］. Clin Cosmet Investig Dermatol, 2014,7:119⁃132. DOI: 10.2147/CCID.S44843.
［50］	Menter A, Strober BE, Kaplan DH, et al. Joint AAD⁃NPF guidelines of care for the management and treatment of psoriasis with biologics［J］. J Am Acad Dermatol, 2019,80（4）:1029⁃1072. DOI: 10.1016/j.jaad.2018.11.057.
［51］	赵冰洁, 张江安, 于建斌, 等. 阿维A对银屑病患者血脂影响的回顾性分析. 临床皮肤科杂志, 2017,46（6）:406⁃408. DOI: 10.16761/j.cnki.1000⁃4963.2017.06.008.
［52］	Antoniou C, Dessinioti C, Katsambas A, et al. Elevated triglyceride and cholesterol levels after intravenous antitumour necrosis factor⁃alpha therapy in a patient with psoriatic arthritis and psoriasis vulgaris［J］. Br J Dermatol, 2007,156（5）:1090⁃1091. DOI: 10.1111/j.1365⁃2133.2007.07835.x.
［53］	Gerdes S, Pinter A, Papavassilis C, et al. Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients［J］. J Eur Acad Dermatol Venereol, 2020,34（3）:533⁃541. DOI: 10.1111/jdv.16004.
［54］	Wang HN, Huang YH. Changes in metabolic parameters in psoriatic patients treated with secukinumab［J］. Ther Adv Chronic Dis, 2020,11:2040622320944777. DOI: 10.1177/204062232094 4777.
［55］	Egeberg A, Wu JJ, Korman N, et al. Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate⁃to⁃severe plaque psoriasis: results from UNCOVER⁃1, UNCOVER⁃2, and UNCOVER⁃3［J］. J Am Acad Dermatol, 2018,79（1）:104⁃109.e8. DOI: 10.1016/j.jaad.2018.02.074.
［56］	乌帕替尼缓释片（瑞福®）说明书［Z/OL］.（2022⁃02⁃18）［2025⁃06⁃20］. http://m.gdpmaa.com/uploads/file1/20240916/%E4%B9%8C%E5%B8%95%E6%9B%BF%E5%B0%BC%E7%BC%93%E9%87%8A%E7%89%87%E8%AF%B4%E6%98%8E%E4%B9%A6%EF%BC%88%E6%9C%80%E6%96%B0%EF%BC%8910_24⁃JXHS2300008⁃SMS⁃20231027093706.pdf.
［57］	Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement［J］. Circulation, 2005,112（17）:2735⁃2752. DOI: 10. 1161/CIRCULATIONAHA.105.169404.
［58］	Alberti KG, Zimmet P, Shaw J, et al. The metabolic syndrome⁃⁃a new worldwide definition［J］. Lancet, 2005,366（9491）:1059⁃1062. DOI: 10.1016/S0140⁃6736（05）67402⁃8.
［59］	Grundy SM, Becker D, Clark LT, et al. Third report of the National Cholesterol Education Program （NCEP） expert panel on detection, evaluation, and treatment of high blood cholesterol in adults （adult treatment panel iii） final report［J］. Circulation，2002,106（25）: 3143⁃3421.
［60］	中华医学会糖尿病学分会. 中国2型糖尿病防治指南（2020年版）［J］. 中华糖尿病杂志, 2021,（4）:315⁃409. DOI: 10.3760/cma.j.cn115791⁃20210221⁃00095.
［61］	Liu L, Cai XC, Sun XY, et al. Global prevalence of metabolic syndrome in patients with psoriasis in the past two decades: current evidence［J］. J Eur Acad Dermatol Venereol, 2022,36（11）:1969⁃1979. DOI: 10.1111/jdv.18296.
［62］	Fernández⁃Armenteros JM, Gómez⁃Arbonés X, Buti⁃Soler M, et al. Psoriasis, metabolic syndrome and cardiovascular risk factors. A population⁃based study［J］. J Eur Acad Dermatol Venereol, 2019,33（1）:128⁃135. DOI: 10.1111/jdv.15159.
［63］	Singh R, Koppu S, Perche PO, et al. The cytokine mediated molecular pathophysiology of psoriasis and its clinical implications［J］. Int J Mol Sci, 2021,22（23）:12793.DOI: 10. 3390/ijms222312793.
［64］	Li X, Zhang D, Vatner DF, et al. Mechanisms by which adiponectin reverses high fat diet⁃induced insulin resistance in mice［J］. Proc Natl Acad Sci U S A, 2020,117（51）:32584⁃32593. DOI: 10.1073/pnas.1922169117.
［65］	Pleńkowska J, Gabig⁃Cimińska M, Mozolewski P. Oxidative stress as an important contributor to the pathogenesis of psoriasis［J］. Int J Mol Sci, 2020,21（17）:6206. DOI: 10.3390/ijms211 76206.
［66］	Han Y, Liu T, Lu L. Apolipoprotein E gene polymorphism in psoriasis: a meta⁃analysis［J］. Arch Med Res, 2013,44（1）:46⁃53. DOI: 10.1016/j.arcmed.2012.10.009.
［67］	Gisondi P, Cazzaniga S, Chimenti S, et al. Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry［J］. J Eur Acad Dermatol Venereol, 2013,27（1）:e30⁃41. DOI: 10.1111/j.1468⁃3083.2012.04450.x.
［68］	Elmets CA, Leonardi CL, Davis D, et al. Joint AAD⁃NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities［J］. J Am Acad Dermatol, 2019,80（4）:1073⁃1113. DOI: 10.1016/j.jaad.2018. 11.058.
［69］	Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology⁃National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies［J］. J Am Acad Dermatol, 2020,82（6）:1445⁃1486. DOI: 10.1016/j.jaad.2020.02.044.
［70］	Gisondi P, Targher G, Zoppini G, et al. Non⁃alcoholic fatty liver disease in patients with chronic plaque psoriasis［J］. J Hepatol, 2009,51（4）:758⁃764. DOI: 10.1016/j.jhep.2009.04.020.
［71］	Gisondi P, Barba E, Girolomoni G. Non⁃alcoholic fatty liver disease fibrosis score in patients with psoriasis［J］. J Eur Acad Dermatol Venereol, 2016,30（2）:282⁃287. DOI: 10.1111/jdv. 13456.
［72］	Roberts KK, Cochet AE, Lamb PB, et al. The prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic［J］. Aliment Pharmacol Ther, 2015,41（3）:293⁃300. DOI: 10.1111/apt.13042.
［73］	Wenk KS, Arrington KC, Ehrlich A. Psoriasis and non⁃alcoholic fatty liver disease［J］. J Eur Acad Dermatol Venereol, 2011,25（4）:383⁃391. DOI: 10.1111/j.1468⁃3083.2010.03841.x.
［74］	Lim S, Kim JW, Targher G. Links between metabolic syndrome and metabolic dysfunction⁃associated fatty liver disease［J］. Trends Endocrinol Metab, 2021,32（7）:500⁃514. DOI: 10.1016/j.tem.2021.04.008.
［75］	Mantovani A, Gisondi P, Lonardo A, et al. Relationship between non⁃alcoholic fatty liver disease and psoriasis: a novel hepato⁃dermal axis?［J］. Int J Mol Sci, 2016,17（2）:217. DOI: 10.3390/ijms17020217.
［76］	Silva FS, Ribeiro MP, Santos MS, et al. Acitretin affects bioenergetics of liver mitochondria and promotes mitochondrial permeability transition: potential mechanisms of hepatotoxicity［J］. Toxicology, 2013,306:93⁃100. DOI: 10.1016/j.tox.2013. 01.020.
［77］	Nast A, Gisondi P, Ormerod AD, et al. European S3⁃guidelines on the systemic treatment of psoriasis vulgaris⁃⁃update 2015⁃⁃short version⁃⁃EDF in cooperation with EADV and IPC［J］. J Eur Acad Dermatol Venereol, 2015,29（12）:2277⁃2294. DOI: 10. 1111/jdv.13354.
［78］	Kalb RE, Strober B, Weinstein G, et al. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference［J］. J Am Acad Dermatol, 2009,60（5）:824⁃837. DOI: 10.1016/j.jaad.2008.11.906.
［79］	Tan KW, Griffiths CE. Novel systemic therapies for the treatment of psoriasis［J］. Expert Opin Pharmacother, 2016,17（1）:79⁃92. DOI: 10.1517/14656566.2016.1109636.
［80］	Yang Q, Qu L, Tian H, et al. Prevalence and characteristics of psoriatic arthritis in Chinese patients with psoriasis［J］. J Eur Acad Dermatol Venereol, 2011,25（12）:1409⁃1414. DOI: 10. 1111/j.1468⁃3083.2011.03985.x.
［81］	Zhang H, Chen M, Cui R, et al. Prevalence of psoriatic arthritis in Chinese population with psoriasis: a multicenter study conducted by experienced rheumatologists［J］. Chin Med J （Engl）, 2023,136（12）:1439⁃1447. DOI: 10.1097/CM9.0000000 000002683.
［82］	苏茵, 王彩虹, 高晋芳, 等. 银屑病关节炎诊疗规范［J］. 中华内科杂志, 2022,61（8）:883⁃892. DOI: 10.3760/cma.j.cn112138⁃20220103⁃00003.
［83］	Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis （GRAPPA）: updated treatment recommendations for psoriatic arthritis 2021［J］. Nat Rev Rheumatol, 2022,18（8）:465⁃479. DOI: 10.1038/s41584⁃022⁃00798⁃0.
［84］	顾军, 戴生明. 中国关节病型银屑病诊疗共识（2020）［J］. 中华皮肤科杂志, 2020,53（8）:585⁃95. DOI: 10.35541/cjd.2020 0369.
［85］	Fu Y, Lee CH, Chi CC. Association of psoriasis with inflammatory bowel disease: a systematic review and meta⁃analysis［J］. JAMA Dermatol, 2018,154（12）:1417⁃1423. DOI: 10.1001/jamadermatol.2018.3631.
［86］	Nehring P, Przybyłkowski A. Is psoriasis treatment a risk factor for inflammatory bowel disease?［J］. Pharmaceut Med, 2020,34（4）:257⁃262. DOI: 10.1007/s40290⁃020⁃00340⁃1.
［87］	Li Y, Guo J, Cao Z, et al. Causal association between inflammatory bowel disease and psoriasis: a two⁃sample bidirectional mendelian randomization study［J］. Front Immunol, 2022,13:916645. DOI: 10.3389/fimmu.2022.916645.
［88］	Moon JM, Lee JY, Koh SJ, et al. Incidence of psoriasis in patients with inflammatory bowel disease: a nationwide population⁃based matched cohort study［J］. Dermatology, 2021,237（3）:330⁃337. DOI: 10.1159/000514030.
［89］	Vlachos C, Gaitanis G, Katsanos KH, et al. Psoriasis and inflammatory bowel disease: links and risks［J］. Psoriasis （Auckl）, 2016,6:73⁃92. DOI: 10.2147/PTT.S85194.
［90］	Conforti C, Dianzani C, Zalaudek I, et al. Spotlight on the treatment armamentarium of concomitant psoriasis and inflammatory bowel disease: a systematic review［J］. J Dermatolog Treat, 2022,33（3）:1279⁃1286. DOI: 10.1080/09546634.2020. 1836313.
［91］	Hedin C, Sonkoly E, Eberhardson M, et al. Inflammatory bowel disease and psoriasis: modernizing the multidisciplinary approach［J］. J Intern Med, 2021,290（2）:257⁃278. DOI: 10.1111/joim.13282.
［92］	Lambert JR, Wright V. Eye inflammation in psoriatic arthritis［J］. Ann Rheum Dis, 1976,35（4）:354⁃356. DOI: 10.1136/ard. 35.4.354.
［93］	Rehal B, Modjtahedi BS, Morse LS, et al. Ocular psoriasis［J］. J Am Acad Dermatol, 2011,65（6）:1202⁃1212. DOI: 10.1016/j.jaad.2010.10.032.
［94］	Abbouda A, Abicca I, Fabiani C, et al. Psoriasis and psoriatic arthritis⁃related uveitis: different ophthalmological manifestations and ocular inflammation features［J］. Semin Ophthalmol, 2017,32（6）:715⁃720. DOI: 10.3109/08820538.2016.1170161.
［95］	Lee Y, Oh BL, Yu HG, et al. Clinical characteristics of uveitis in patients with psoriasis in Korea: a retrospective multicenter case series［J］. Korean J Ophthalmol, 2021,35（1）:64⁃72. DOI: 10. 3341/kjo.2020.0131.
［96］	El⁃Asrar AM, Struyf S, Kangave D, et al. Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis［J］. Clin Immunol, 2011,139（2）:177⁃184. DOI: 10.1016/j.clim.2011.01.014.
［97］	Chandran NS, Greaves M, Gao F, et al. Psoriasis and the eye: prevalence of eye disease in Singaporean Asian patients with psoriasis［J］. J Dermatol, 2007,34（12）:805⁃810. DOI: 10.1111/j.1346⁃8138.2007.00390.x.
［98］	Slabaugh MA, Herlihy E, Ongchin S, et al. Efficacy and potential complications of difluprednate use for pediatric uveitis［J］. Am J Ophthalmol, 2012,153（5）:932⁃938. DOI: 10.1016/j.ajo.2011.10.008.
［99］	Rathinam SR, Babu M, Thundikandy R, et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis［J］. Ophthalmology, 2014,121（10）:1863⁃
	1870. DOI: 10.1016/j.ophtha.2014.04.023.
［100］	Kaçmaz RO, Kempen JH, Newcomb C, et al. Cyclosporine for ocular inflammatory diseases［J］. Ophthalmology, 2010,117（3）:576⁃584. DOI: 10.1016/j.ophtha.2009.08.010.
［101］	Huynh N, Cervantes⁃Castaneda RA, Bhat P, et al. Biologic response modifier therapy for psoriatic ocular inflammatory disease［J］. Ocul Immunol Inflamm, 2008,16（3）:89⁃93. DOI: 10.1080/09273940802023786.
［102］	Jadon DR, Corp N, van der Windt DA, et al. Management of concomitant inflammatory bowel disease or uveitis in patients with psoriatic arthritis: an updated review informing the 2021 GRAPPA treatment recommendations［J］. J Rheumatol, 2023,50（3）:438⁃450. DOI: 10.3899/jrheum.220317.
［103］	Dick AD, Tugal⁃Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials［J］. Ophthalmology, 2013,120（4）:777⁃787. DOI: 10.1016/j.ophtha.2012.09.040.
［104］	Burmester GR, Gordon KB, Rosenbaum JT, et al. Long⁃term safety of adalimumab in 29,967 adult patients from global clinical trials across multiple indications: an updated analysis［J］. Adv Ther, 2020,37（1）:364⁃380. DOI: 10.1007/s12325⁃019⁃01145⁃8.
［105］	Islam MM, Poly TN, Yang HC, et al. Increase risk of multiple sclerosis in patients with psoriasis disease: an evidence of observational studies［J］. neuroepidemiology, 2019,52（3⁃4）:152⁃160. DOI: 10.1159/000495112.
［106］	Patrick MT, Nair RP, He K, et al. Shared genetic risk factors for multiple sclerosis/psoriasis suggest involvement of interleukin⁃17 and Janus kinase⁃signal transducers and activators of transcription signaling［J］. Ann Neurol, 2023,94（2）:384⁃397. DOI: 10.1002/ana.26672.
［107］	Berna⁃Rico E, Perez⁃Bootello J, Abbad⁃Jaime de Aragon C, et al. Genetic influence on treatment response in psoriasis: new insights into personalized medicine［J］. Int J Mol Sci, 2023,24（12）:9850. DOI: 10.3390/ijms24129850.
［108］	Griffiths C, Armstrong AW, Gudjonsson JE, et al. Psoriasis［J］. Lancet, 2021,397（10281）:1301⁃1315. DOI: 10.1016/S0140⁃6736（20）32549⁃6.
［109］	Sukal SA, Nadiminti L, Granstein RD. Etanercept and demyelinating disease in a patient with psoriasis［J］. J Am Acad Dermatol, 2006,54（1）:160⁃164. DOI: 10.1016/j.jaad.2005. 05.039.
［110］	Herrera⁃Acosta E, Garriga⁃Martina GG, Suárez⁃Pérez JA, et al. Ixekizumab for patients with plaque psoriasis affected by multiple sclerosis: case report［J］. Sultan Qaboos Univ Med J, 2021,21（3）:488⁃490. DOI: 10.18295/squmj.4.2021.021.
［111］	Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti⁃interleukin⁃23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phaseⅢ, double⁃blinded, placebo⁃ and active comparator⁃controlled VOYAGE 1 trial［J］. J Am Acad Dermatol, 2017,76（3）:405⁃417. DOI: 10.1016/j.jaad.2016.11.041.
［112］	Hosseini A, Gharibi T, Mohammadzadeh A, et al. Ruxolitinib attenuates experimental autoimmune encephalomyelitis （EAE） development as animal models of multiple sclerosis （MS）［J］. Life Sci, 2021,276:119395. DOI: 10.1016/j.lfs.2021.119395.
［113］	Dang C, Lu Y, Chen X, et al. Baricitinib ameliorates experimental autoimmune encephalomyelitis by modulating the janus kinase/signal transducer and activator of transcription signaling pathway［J］. Front Immunol, 2021,12:650708. DOI: 10.3389/fimmu.2021.650708.
［114］	Tsai YC, Tsai TF. Overlapping features of psoriasis and atopic dermatitis: from genetics to immunopathogenesis to phenotypes［J］. Int J Mol Sci, 2022,23（10）:5518. DOI: 10.3390/ijms231 05518.
［115］	Mortlock RD, Ma EC, Cohen JM, et al. Assessment of treatment⁃relevant immune biomarkers in psoriasis and atopic dermatitis: toward personalized medicine in dermatology［J］. J Invest Dermatol, 2023,143（8）:1412⁃1422. DOI: 10.1016/j.jid.2023. 04.005.
［116］	Bain KA, McDonald E, Moffat F, et al. Alopecia areata is characterized by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease⁃associated psychological morbidity［J］. Br J Dermatol, 2020,182（1）:130⁃137. DOI: 10.1111/bjd.18008.
［117］	Loh SH, Moon HN, Lew BL, et al. Role of T helper 17 cells and T regulatory cells in alopecia areata: comparison of lesion and serum cytokine between controls and patients［J］. J Eur Acad Dermatol Venereol, 2018,32（6）:1028⁃1033. DOI: 10.1111/jdv. 14775.
［118］	Gautam RK, Singh Y, Gupta A, et al. The profile of cytokines （IL⁃2, IFN⁃γ, IL⁃4, IL⁃10, IL⁃17A, and IL⁃23） in active alopecia areata［J］. J Cosmet Dermatol, 2020,19（1）:234⁃240. DOI: 10.1111/jocd.12970.
［119］	Dai Z, Wang E, Petukhova L, et al. Blockade of IL⁃7 signaling suppresses inflammatory responses and reverses alopecia areata in C3H/HeJ mice［J］. Sci Adv, 2021,7（14）:eabd1866. DOI: 10. 1126/sciadv.abd1866.
［120］	Zhou J, An X, Dong J, et al. IL⁃17 induces cellular stress microenvironment of melanocytes to promote autophagic cell apoptosis in vitiligo［J］. FASEB J, 2018,32（9）:4899⁃4916. DOI: 10.1096/fj.201701242RR.
［121］	章星琪. JAK抑制剂治疗斑秃的现状、前景及其启示［J］. 皮肤性病诊疗学杂志, 2022,29（2）:93⁃100.
［122］	刘婉雯, 郭美亮, 孟琴琴, 等. JAK抑制剂在银屑病治疗中的研究进展［J］. 中国麻风皮肤病杂志, 2021,37（10）:684⁃688. DOI: 10.12144/zgmfskin202110684.
［123］	白璐, 朱才勇. JAK抑制剂在皮肤科的应用进展［J］. 实用皮肤病学杂志, 2023,16（1）:28⁃32.
［124］	Miot HA, Criado PR, de Castro C, et al. JAK⁃STAT pathway inhibitors in dermatology［J］. An Bras Dermatol, 2023,98（5）:656⁃677. DOI: 10.1016/j.abd.2023.03.001.
［125］	Dalmády S, Kemény L, Antal M, et al. Periodontitis: a newly identified comorbidity in psoriasis and psoriatic arthritis［J］. Expert Rev Clin Immunol, 2020,16（1）:101⁃108. DOI: 10.1080/1744666X.2019.1700113.
［126］	涂洁, 尹志强. 银屑病并发症的研究进展［J］. 中国麻风皮肤病杂志, 2019,35（02）:120⁃123.
［127］	Parisi R, Webb RT, Kleyn CE, et al. Psychiatric morbidity and suicidal behaviour in psoriasis: a primary care cohort study［J］. Br J Dermatol, 2019,180（1）:108⁃115. DOI: 10.1111/bjd.17004.
［128］	Wu JJ, Feldman SR, Koo J, et al. Epidemiology of mental health comorbidity in psoriasis［J］. J Dermatolog Treat, 2018,29（5）:487⁃495. DOI: 10.1080/09546634.2017.1395800.
［129］	陈文娟, 彭琛, 丁杨峰,等. 银屑病共病的研究进展［J］. 中华皮肤科杂志, 2020,53（2）:5. DOI: 10.35541/cjd.20190093.
［130］	史玉玲. 银屑病相关心理问题和精神障碍［J］. 皮肤科学通报, 2021,38（2）:108⁃112+3.
［131］	Hedemann TL, Liu X, Kang CN, et al. Associations between psoriasis and mental illness: an update for clinicians［J］. Gen Hosp Psychiatry, 2022,75:30⁃37. DOI: 10.1016/j.genhosppsych. 2022.01.006.
［132］	Liu L, Lin NX, Yu YT, et al. Epidemiology of mental health comorbidity in patients with psoriasis: an analysis of trends from 1986 to 2019［J］. Psychiatry Res, 2023,321:115078. DOI: 10.1016/j.psychres.2023.115078.
［133］	Singh S, Taylor C, Kornmehl H, et al. Psoriasis and suicidality: a systematic review and meta⁃analysis［J］. J Am Acad Dermatol, 2017,77（3）:425⁃440.e2. DOI: 10.1016/j.jaad.2017.05.019.
［134］	王倩, 江水, 陈官芝, 等. 银屑病患者抑郁和焦虑的调查及其对共患病的影响［J］. 中国麻风皮肤病杂志, 2020,36（10）: 584⁃587,604. DOI: 10.12144/zgmfskin202010584.
［135］	尹先勇. 银屑病全基因组关联分析中遗传性缺失的研究［D］. 安徽: 安徽医科大学, 2014. DOI: 10.7666/d.D618555.
［136］	Daugaard C, Iversen L, Hjuler KF. Comorbidity in adult psoriasis: considerations for the clinician［J］. Psoriasis （Auckl）, 2022,12:139⁃150. DOI: 10.2147/PTT.S328572.
［137］	Daudén E, Castañeda S, Suárez C, et al. Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis［J］. J Eur Acad Dermatol Venereol, 2013,27（11）:1387⁃1404. DOI: 10.1111/jdv.12024.
［138］	Strober B, Gooderham M, de Jong E, et al. Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry （PSOLAR）［J］. J Am Acad Dermatol, 2018,78（1）:70⁃80. DOI: 10.1016/j.jaad.2017.08.051.
［139］	Langley RG, Feldman SR, Han C, et al. Ustekinumab significantly improves symptoms of anxiety, depression, and skin⁃related quality of life in patients with moderate⁃to⁃severe psoriasis: results from a randomized, double⁃blind, placebo⁃controlled phaseⅢ trial［J］. J Am Acad Dermatol, 2010,63（3）:457⁃465. DOI: 10.1016/j.jaad.2009.09.014.
［140］	Gordon KB, Armstrong AW, Han C, et al. Anxiety and depression in patients with moderate⁃to⁃severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the phase 3 VOYAGE 2 study［J］. J Eur Acad Dermatol Venereol, 2018,32（11）:1940⁃1949. DOI: 10.1111/jdv.15012.
［141］	Reich K, Foley P, Han C, et al. Guselkumab improves work productivity in patients with moderate⁃to⁃severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab［J］. J Dermatolog Treat, 2020,31（6）:617⁃623. DOI: 10.1080/09546634.2019.1628172.
［142］	胡中慧, 孙青. 生物制剂治疗银屑病共病研究进展［J］. 中国麻风皮肤病杂志, 2021,37（7）:471⁃476. DOI: 10.12144/zgmfskin 202107471.
［143］	Chiesa Fuxench ZC, Shin DB, Ogdie Beatty A, et al. The risk of cancer in patients with psoriasis: a population⁃based cohort study in the health improvement network［J］. JAMA Dermatol, 2016,152（3）:282⁃290. DOI: 10.1001/jamadermatol.2015.4847.
［144］	李秀珍, 徐秀莲. 白细胞介素23抑制剂治疗对银屑病共病的影响［J］. 中华皮肤科杂志, 2025,58（3）:268⁃272. DOI: 10. 35541/cjd.20210809.
［145］	Vaengebjerg S, Skov L, Egeberg A, et al. Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: a systematic review and meta⁃analysis［J］. JAMA Dermatol, 2020,156（4）:421⁃429. DOI: 10.1001/jamadermatol. 2020.0024.
［146］	Polachek A, Muntyanu A, Lee KA, et al. Malignancy in psoriatic disease: results from prospective longitudinal cohorts［J］. Semin Arthritis Rheum, 2021,51（1）:144⁃149. DOI: 10. 1016/j.semarthrit.2020.12.008.
［147］	Loft ND, Vaengebjerg S, Skov L. Cancer risk in patients with psoriasis: should we be paying more attention?［J］. Expert Rev Clin Immunol, 2020,16（5）:479⁃492. DOI: 10.1080/1744666X. 2020.1754194.
［148］	贺旭, 毕新岭, 陶苏江. 银屑病并发常见皮肤恶性肿瘤的研究现状［J］. 中国皮肤性病学杂志, 2023,37（7）:733⁃737. DOI: 10.13735/j.cjdv.1001⁃7089.202206041.
［149］	Sun LD. Research progress of genomic variation in psoriasis［J］. Int J Dermatol Venerol, 2022, 5（4）: 207⁃212. DOI: 10.1097/ jd9.0000000000000276.
［150］	Perez⁃Chada LM, Merola JF. Comorbidities associated with psoriatic arthritis: review and update. Clin Immunol, 2020,214:108397. DOI: 10.1016/j.clim.2020.108397.
［151］	蔡仕良, 蒲蕊, 柳东红, 等. 筛查在三类恶性肿瘤精准预防策略中的意义［J］. 上海预防医学, 2022,34（7）:705⁃711. DOI: 10.19428/j.cnki.sjpm.2022.21705.
［152］	Geller S, Xu H, Lebwohl M, et al. Malignancy risk and recurrence with psoriasis and its treatments: a concise update［J］. Am J Clin Dermatol, 2018,19（3）:363⁃375. DOI: 10.1007/s40257⁃017⁃0337⁃2.
［153］	Archier E, Devaux S, Castela E, et al. Carcinogenic risks of psoralen UV⁃A therapy and narrowband UV⁃B therapy in chronic plaque psoriasis: a systematic literature review［J］. J Eur Acad Dermatol Venereol, 2012,26 Suppl 3:22⁃31. DOI: 10.1111/j.1468⁃3083.2012.04520.x.
［154］	Åkerla P, Pukkala E, Helminen M, et al. Skin cancer risk of narrow⁃band UV⁃B （TL⁃01） phototherapy: a multi⁃center registry study with 4,815 patients［J］. Acta Derm Venereol, 2024,104:adv39927. DOI: 10.2340/actadv.v104.39927.
［155］	Wang E, Ahad T, Liu YA, et al. Incidence and profile of skin cancers in patients following ultraviolet phototherapy without psoralens: a retrospective cohort study［J］. J Am Acad Dermatol, 2024,90（4）:759⁃766. DOI: 10.1016/j.jaad.2023.11. 053.
［156］	Carretero G, Ferrandiz C, Dauden E, et al. Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5⁃year observational study of clinical practice: 2008⁃2013 results of the Biobadaderm registry［J］. J Eur Acad Dermatol Venereol, 2015,29（1）:156⁃163. DOI: 10.1111/jdv. 12492.
［157］	Paul CF, Ho VC, McGeown C, et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study［J］. J Invest Dermatol, 2003,120（2）:211⁃216. DOI: 10.1046/j.1523⁃1747.2003.12040.x.
［158］	Marcil I, Stern RS. Squamous⁃cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study［J］. Lancet, 2001,358（9287）:1042⁃1045. DOI: 10.1016/S0140⁃6736（01）06179⁃7.
［159］	Papp K, Gottlieb AB, Naldi L, et al. Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry （PSOLAR）［J］. J Drugs Dermatol, 2015,14（7）:706⁃714.
［160］	Reich K, Mrowietz U, Radtke MA, et al. Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest［J］. Arch Dermatol Res, 2015,307（10）:875⁃883. DOI: 10.1007/s00403⁃015⁃1593⁃8.
［161］	Barth D, Simon JC, Wetzig T. Malignant melanoma during treatment with fumaric acid esters ⁃ coincidence or treatment⁃related?［J］. J Dtsch Dermatol Ges, 2011,9（3）:223⁃225. DOI: 10.1111/j.1610⁃0387.2010.07479.x.
［162］	Horvat TZ, Adel NG, Dang TO, et al. Immune⁃related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center［J］. J Clin Oncol, 2015,33（28）:3193⁃3198. DOI: 10.1200/JCO.2015.60.8448.
［163］	Lebwohl M, Deodhar A, Griffiths C, et al. The risk of malignancy in patients with secukinumab⁃treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow⁃up［J］. Br J Dermatol, 2021,185（5）:935⁃944. DOI: 10.1111/bjd.20136.
［164］	Strober B, Leonardi C, Papp KA, et al. Short⁃ and long⁃term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: etanercept comparisons and integrated data［J］. J Am Acad Dermatol, 2017,76（3）:432⁃440.e17. DOI: 10.1016/j.jaad. 2016.09.026.
［165］	Blauvelt A, Tsai TF, Langley RG, et al. Consistent safety profile with up to 5 years of continuous treatment with guselkumab: pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate⁃to⁃severe psoriasis［J］. J Am Acad Dermatol, 2022,86（4）:827⁃834. DOI: 10.1016/j.jaad.2021. 11.004.
［166］	Bernardini N, Skroza N, Marchesiello A, et al. Psoriatic patients with a history of cancer: a real⁃life experience with apremilast treatment for 104 weeks［J］. Dermatol Ther, 2022,35（10）:e15306. DOI: 10.1111/dth.15306.
［167］	Ozdede A, Yazici H. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med, 2022,386（18）:1766. DOI: 10.1056/NEJMc2202778.
［168］	Wan J, Wang S, Haynes K, et al. Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study［J］. BMJ, 2013,347:f5961. DOI: 10.1136/bmj.f5961.
［169］	Chi CC, Wang J, Chen YF, et al. Risk of incident chronic kidney disease and end⁃stage renal disease in patients with psoriasis: a nationwide population⁃based cohort study［J］. J Dermatol Sci, 2015,78（3）:232⁃238. DOI: 10.1016/j.jdermsci. 2015.03.012.
［170］	字佳琦, 邓丹琪. 银屑病合并肾脏损害的发病机制及临床表现［J］. 中国麻风皮肤病杂志, 2022,38（9）:659⁃663. DOI: 10.12144/zgmfskin202209659.
［171］	Kvist⁃Hansen A, Kaiser H, Skov L, et al. Comorbidity in connection with psoriasis is more than psoriatic arthritis［J］. Ugeskr Laeger, 2018,180（2）:V07170526 ［pii］.
［172］	González⁃Parra E, Daudén E, Carrascosa JM, et al. Kidney disease and psoriasis. a new comorbidity?［J］. Actas Dermosifiliogr, 2016,107（10）:823⁃829. DOI: 10.1016/j.ad.2016. 05.009.
［173］	Chen CB, Huang YT, Hsiao CC, et al. Real⁃world effects of biologics on renal function in psoriatic patients: a retrospective study［J］. BioDrugs, 2022,36（5）:657⁃666. DOI: 10.1007/s40259⁃022⁃00547⁃5.
［174］	Kao LT, Lee CZ, Liu SP, et al. Psoriasis and the risk of pneumonia: a population⁃based study［J］. PLoS One, 2014,9（12）:e116077. DOI: 10.1371/journal.pone.0116077.
［175］	Martin A, Thatiparthi A, Liu J, et al. Association between psoriasis and asthma among United States adults in the 2009-2014 National Health and Nutrition Examination Survey［J］. J Am Acad Dermatol, 2022,86（3）:709⁃712. DOI: 10.1016/j.jaad. 2021.04.027.
［176］	Wang J, Ke R, Shi W, et al. Association between psoriasis and asthma risk: a meta⁃analysis［J］. Allergy Asthma Proc, 2018,39（2）:103⁃109. DOI: 10.2500/aap.2018.39.4109.
［177］	Joel MZ, Fan R, Damsky W, et al. Psoriasis associated with asthma and allergic rhinitis: a US⁃based cross⁃sectional study using the all of US research program［J］. Arch Dermatol Res, 2023,315（6）:1823⁃1826. DOI: 10.1007/s00403⁃023⁃02539⁃z.
［178］	Li X, Kong L, Li F, et al. Association between psoriasis and chronic obstructive pulmonary disease: a systematic review and meta⁃analysis［J］. PLoS One, 2015,10（12）:e0145221. DOI: 10.1371/journal.pone.0145221.
［179］	Damiani G, Radaeli A, Olivini A, et al. Increased airway inflammation in patients with psoriasis［J］. Br J Dermatol, 2016,175（4）:797⁃799. DOI: 10.1111/bjd.14546.
［180］	Östling J, van Geest M, Schofield J, et al. IL⁃17⁃high asthma with features of a psoriasis immunophenotype［J］. J Allergy Clin Immunol, 2019,144（5）:1198⁃1213. DOI: 10.1016/j.jaci. 2019.03.027.
［181］	Sigurdardottir SL, Thorleifsdottir RH, Valdimarsson H, et al. The association of sore throat and psoriasis might be explained by histologically distinctive tonsils and increased expression of skin⁃homing molecules by tonsil T cells［J］. Clin Exp Immunol, 2013,174（1）:139⁃151. DOI: 10.1111/cei.12153.
［182］	Totté JE, van der Feltz WT, Bode LG, et al. A systematic review and meta⁃analysis on Staphylococcus aureus carriage in psoriasis, acne and rosacea［J］. Eur J Clin Microbiol Infect Dis, 2016,35（7）:1069⁃1077. DOI: 10.1007/s10096⁃016⁃2647⁃3.
［183］	Shalom G, Dreiher J, Cohen A. Psoriasis and obstructive sleep apnea［J］. Int J Dermatol, 2016,55（11）:e579⁃e584. DOI: 10. 1111/ijd.13367.
［184］	Dalgard FJ, Gieler U, Tomas⁃Aragones L, et al. The psychological burden of skin diseases: a cross⁃sectional multicenter study among dermatological out⁃patients in 13 European countries［J］. J Invest Dermatol, 2015,135（4）:984⁃991. DOI: 10.1038/jid.2014.530.
［185］	Leibowitz E, Seidman DS, Laor A, et al. Are psoriatic patients at risk of heat intolerance?［J］. Br J Dermatol, 1991,124（5）:439⁃442. DOI: 10.1111/j.1365⁃2133.1991.tb00622.x.
［186］	Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review［J］. JAMA, 2020,323（19）:1945⁃1960. DOI: 10.1001/jama.2020.4006.
［187］	Nadeem A, Al⁃Harbi NO, Ansari MA, et al. Psoriatic inflammation enhances allergic airway inflammation through IL⁃23/STAT3 signaling in a murine model［J］. Biochem Pharmacol, 2017,124:69⁃82. DOI: 10.1016/j.bcp.2016.10.012.
［188］	Amarnani A, Rosenthal KS, Mercado JM, et al. Concurrent treatment of chronic psoriasis and asthma with ustekinumab［J］. J Dermatolog Treat, 2014,25（1）:63⁃66. DOI: 10.3109/09546634.2013.782095.
［189］	中华医学会老年医学分会老年内分泌代谢疾病学组, 中华医学会内分泌学分会甲状腺学组. 中国老年人甲状腺疾病诊疗专家共识（2021）［J］. 中华内分泌代谢杂志, 2021,37（5）:399⁃418. DOI: 10.3760/cma.j.cn311282⁃20210502⁃00273.
［190］	Ungprasert P, Wijarnpreecha K, Wetter DA. Periodontitis and risk of psoriasis: a systematic review and meta⁃analysis［J］. J Eur Acad Dermatol Venereol, 2017,31（5）:857⁃862. DOI: 10. 1111/jdv.14051.
［191］	Sharma A, Raman A, Pradeep AR. Association of chronic periodontitis and psoriasis: periodontal status with severity of psoriasis［J］. Oral Dis, 2015,21（3）:314⁃319. DOI: 10.1111/odi. 12271.
［192］	Leisner MZ, Riis JL, Schwartz S, et al. Psoriasis and risk of mental disorders in Denmark［J］. JAMA Dermatol, 2019,155（6）:745⁃747. DOI: 10.1001/jamadermatol.2019.0039.
［193］	Nowowiejska J, Baran A, Flisiak I. Psoriasis and neurodegenerative diseases⁃a review［J］. Front Mol Neurosci, 2022,15:917751. DOI: 10.3389/fnmol.2022.917751.
［194］	中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南（2022）［J］. 中国全科医学, 2023,26（14）:1671⁃1691. DOI: 10.12114/j.issn.1007⁃9572.2023.0121.
［195］	D'Epiro S, Marocco C, Salvi M, et al. Psoriasis and bone mineral density: implications for long⁃term patients［J］. J Dermatol, 2014,41（9）:783⁃787. DOI: 10.1111/1346⁃8138.12546.
［196］	Li YY, Dong RJ, Cao LJ, et al. Case of coincident severe acne and psoriasis in AIDS patient successfully treated with antiretroviral therapy［J］. J Dermatol, 2019,46（5）:431⁃435. DOI: 10.1111/1346⁃8138.14823.
［197］	Agamia NF, Abdallah DM, Sorour O, et al. Skin expression of mammalian target of rapamycin and forkhead box transcription factor O1, and serum insulin⁃like growth factor⁃1 in patients with acne vulgaris and their relationship with diet［J］. Br J Dermatol, 2016,174（6）:1299⁃1307. DOI: 10.1111/bjd.14409.

[1]	“Chinese expert consensus on the clinical application of photobiomodulation therapy in dermatology （）”解读专家组中华医学会皮肤性病学分会激光学组. [开放获取] 2025版光生物调节疗法在皮肤科的临床应用中国专家共识要点解读[J]. 中华皮肤科杂志, 2026, 59(3): 208-212.
[2]	王钧程刘洁. [开放获取] 人工智能在银屑病临床诊疗与患者管理中的应用进展[J]. 中华皮肤科杂志, 2026, 0(3): 20240061-e20240061.
[3]	郭澜晋红中. 色氨酸和精氨酸代谢对免疫反应的调控机制及其在银屑病发病中的作用研究进展[J]. 中华皮肤科杂志, 2026, 0(3): 20240377-e20240377.
[4]	中华医学会皮肤性病学分会中国医师协会皮肤科医师分会中国医疗保健国际交流促进会皮肤医学分会中国罕见病联盟皮肤罕见病专业委员会. [开放获取] 佩索利单抗治疗炎症性皮肤病专家共识（2026版）[J]. 中华皮肤科杂志, 2026, 59(2): 113-119.
[5]	袁瑾曾晓丽林粼吴汶霖黄悦周昆丽蔡良奇. 关节病型银屑病患者血清中成纤维细胞生长因子23的表达及其临床意义[J]. 中华皮肤科杂志, 2026, 59(1): 58-61.
[6]	《疥疮诊疗中国专家共识（版）》编写委员会专家组. 疥疮诊疗中国专家共识（2026版）[J]. 中华皮肤科杂志, 2026, 59(1): 1-8.
[7]	中华医学会皮肤性病学分会中国医师协会皮肤科医师分会中国中西医结合学会皮肤性病专业委员会中国非公立医疗机构协会皮肤专业委员会. [开放获取] 玫瑰痤疮患者教育指导专家共识（2026版）[J]. 中华皮肤科杂志, 2026, 0(1): 20240725-e20240725.
[8]	薛天萍陆振中王洪生. [开放获取] 银屑病发病机制与微生物菌群相关性研究进展[J]. 中华皮肤科杂志, 2026, 59(1): 89-92.
[9]	中国医师协会皮肤科医师分会痤疮学组中国研究型医院学会皮肤科学专业委员会中国中西医结合学会皮肤性病专业委员会痤疮学组. [开放获取] 寻常痤疮临床严重度分级及疗效评价中国专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(8): 709-714.
[10]	中华医学会皮肤性病学分会中国医师协会皮肤科医师分会. [开放获取] 局限性硬皮病诊疗专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(8): 699-708.
[11]	李昱王紫薇叶容嘉李容朱艳张小华黄丹鞠梅. 白癜风患者家庭光疗实施及管理需求调查分析[J]. 中华皮肤科杂志, 2025, 58(7): 608-612.
[12]	钟玉玲乐娅冯锦莲陈慕刁. 中国皮肤科瘙痒护理现状分析：基于对85家公立医院607名护士的调查[J]. 中华皮肤科杂志, 2025, 58(7): 613-617.
[13]	中华医学会皮肤性病学分会中国医师协会皮肤科医师分会. [开放获取] 遗传性血管性水肿诊疗路径皮肤科专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(6): 497-502.
[14]	中华医学会皮肤性病学分会银屑病学组. [开放获取] 阿普米司特治疗银屑病专家指导意见（2025版）[J]. 中华皮肤科杂志, 2025, 58(5): 416-424.
[15]	中国儿童鲜红斑痣诊断和治疗专家共识制订专家组中国医师协会皮肤科医师分会儿童学组. [开放获取] 儿童鲜红斑痣诊疗专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(5): 396-404.

伴共病的银屑病管理共识（2026版）

Expert consensus on management of psoriasis with comorbidities （2026）

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 197

相关文章 15

Metrics

本文评价

推荐阅读 10